Journal of Computational Analysis and Applications VOL. 33, NO. 6, 2024
10.48047/jocaaa.2024.33.06.121

# The Role of Low FODMAP Diet in the Management of Irritable Bowel Syndrome: A Comprehensive Review

**Nancy William Boshra Habib[1], Nearmeen M. Rashad[2], Nora Nabil Hussien[1]**

1 Family Medicine Department, Faculty of Medicine, Zagazig University
2 Internal Medicine Department, Faculty of Medicine, Zagazig University
Corresponding Author: Nancy William Boshra Habib

## ABSTRACT

**Background:** Irritable bowel syndrome (IBS) is a prevalent, chronic disorder of gut–brain interaction characterized by abdominal pain and altered bowel habits, often aggravated by meals. As patient priorities have shifted toward lifestyle and nonpharmacologic options, dietary therapy has become central to care. The low FODMAP diet (LFD) restricts fermentable oligo-, di-, monosaccharides and polyols—carbohydrates that are osmotically active and rapidly fermented—thereby reducing gas, luminal distension, and symptom provocation in susceptible individuals. The LFD is delivered in three phases (restriction, reintroduction, personalization) and works best with dietitian guidance. To synthesize the rationale, evidence, and implementation of the LFD in adult IBS; compare the LFD with alternative dietary strategies; discuss benefits and limitations including nutritional adequacy and microbiome effects; review adherence and patient selection; and outline the role of family medicine–led multidisciplinary care and priorities for future research.

**Conclusion:** Randomized controlled trials and multiple meta-analyses demonstrate that the LFD improves global IBS symptoms—especially abdominal pain, bloating, and bowel habit disturbance—across subtypes, with short-term response rates commonly 50–80%. Sustained benefit is achievable when restriction (2–6 weeks) is followed by structured reintroduction to identify personal triggers and long-term personalization to the least-restrictive pattern compatible with symptom control. Quality of life frequently improves, and psychological distress can lessen in step with symptom relief. However, the diet is complex, may increase cost and burden, and prolonged strict restriction risks nutrient shortfalls and microbiome changes if unsupervised. Best practice emphasizes careful triage (including screening for disordered eating and malnutrition risk), dietitian-led education, culturally sensitive food substitutions, and ongoing review to broaden diet diversity. In primary care, family physicians can coordinate stepped care, integrate LFD with pharmacologic and behavioral therapies, and monitor safety and outcomes. Future work should include long-term, adequately powered trials; standardized outcome measures; head-to-head comparisons; and microbiome-informed personalization strategies to enhance effectiveness and equity. When implemented properly, the LFD is an effective, patient-centered intervention that can be tailored to individual tolerance while minimizing unintended consequences.

**Keywords:** *Low FODMAP Diet , Irritable Bowel Syndrome, Comprehensive Review*

## Introduction

10.48047/jocaaa.2024.33.06.121

IBS imposes a substantial burden of symptoms, impaired quality of life, and healthcare utilization worldwide, with many patients reporting meal-related exacerbations that prioritize diet as a therapeutic target. Clinicians increasingly incorporate dietary counseling into routine pathways, reflecting patient preferences for nonpharmacologic options and the maturing evidence base for structured dietary interventions. Within this context, the LFD has emerged as a leading option because it is mechanistically plausible, protocolized, and supported by growing trial and real-world data [1–3].

FODMAPs comprise poorly absorbed, osmotically active short-chain carbohydrates that undergo rapid fermentation, increasing intraluminal water and gas, thereby provoking distension and symptoms in individuals with visceral hypersensitivity and motility disturbances. By transiently restricting high-FODMAP foods and then systematically reintroducing them, clinicians can identify personal thresholds and triggers, allowing a long-term personalized plan that balances symptom relief with nutritional adequacy [4–6].

Despite its promise, gaps remain. Evidence on long-term efficacy and safety is still evolving, especially regarding nutritional sufficiency, microbiome alterations, and sustainability in routine practice. The restrictive complexity of the LFD may hinder access and adherence, particularly in socioeconomically disadvantaged populations, underscoring the need for tailored strategies and physician–dietitian collaboration. Future research should also focus on biomarkers to identify responders and predictive tools for personalizing reintroduction thresholds [7–9].

### A. Pathophysiology of IBS and the Role of Diet

IBS is a disorder of gut–brain interaction in which altered motility, visceral hypersensitivity, immune activation, and psychosocial stressors interact to produce fluctuating gastrointestinal symptoms. A central feature is the exaggerated sensory response to luminal distension, which makes even physiologic gas or fluid loads uncomfortable. This heightened visceral perception explains why diet-induced changes in intestinal content can precipitate disproportionate pain and bloating [10–12].

Food intolerance and hypersensitivity are increasingly recognized as contributors to symptom generation in IBS. Even in the absence of classical allergies, many patients describe consistent triggers related to meals. Experimental studies suggest that certain foods can amplify low-grade inflammation, increase gut permeability, and worsen dysmotility, thereby linking dietary exposures to pathophysiology. This reinforces the rationale for dietary modification as a primary therapeutic strategy in IBS management [13,14].

The impact of diet on gut microbiota is also central. A diet rich in fermentable carbohydrates can shift bacterial composition, reduce diversity, and promote gas-producing species, thereby augmenting symptoms. Conversely, restricting fermentable carbohydrates modifies fermentation substrates, reduces colonic gas, and attenuates luminal distension. These effects provide a mechanistic explanation for the symptomatic benefits seen in patients following a structured LFD [15,16].

10.48047/jocaaa.2024.33.06.121

Beyond local gut effects, the role of diet extends to the gut–brain axis. Fermentation products such as short-chain fatty acids influence motility, visceral sensitivity, and even central nervous system signaling. Dysregulated fermentation in IBS may therefore perpetuate abdominal pain and altered bowel habits, while dietary interventions that stabilize substrate availability may help restore equilibrium in gut–brain communication. This bidirectional interplay positions diet as both a trigger and therapeutic target [17,18].

In clinical practice, appreciating diet's contribution to IBS pathophysiology is essential. Patients often perceive their symptoms as food-related, and ignoring this link can undermine therapeutic rapport. By validating these concerns and providing structured dietary options such as the LFD, clinicians can address patient expectations, reduce symptom burden, and foster engagement with holistic management strategies that extend beyond pharmacology [19,20].

### B. Concept and Mechanism of the Low FODMAP Diet

The term **FODMAP** (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) was first introduced by Gibson and Shepherd at Monash University in 2005. Originally explored in Crohn's disease, its primary clinical application quickly shifted to IBS. This classification brought together diverse poorly absorbed carbohydrates under a unified framework, enabling clinicians and researchers to systematically study their collective impact on gastrointestinal symptoms [21,22].

Mechanistically, FODMAPs share two key traits: poor absorption in the small intestine and rapid fermentation by colonic bacteria. Their osmotic effect increases intestinal water content, while bacterial fermentation produces gas and short-chain fatty acids. In healthy individuals, these processes may be well tolerated. However, in patients with visceral hypersensitivity and impaired motility, even modest luminal distension can trigger bloating, cramping, and altered stool form [23,24].

The first clinical study validating this concept appeared in 2006, showing that 74% of IBS patients with fructose malabsorption improved when following a low-fructose/fructan diet. These early findings laid the groundwork for subsequent randomized controlled trials that tested the broader LFD framework. Importantly, a double-blind rechallenge study in 2008 confirmed that symptom relapse occurred upon reintroduction of fructans and fructose, strengthening the causal link between FODMAPs and IBS symptoms [25,26].

The LFD is not a simple one-step exclusion diet but rather a structured, three-phase intervention. The **restriction phase** eliminates high-FODMAP foods for 2–6 weeks; the **reintroduction phase** systematically tests individual FODMAP groups to determine tolerance; and the **personalization phase** constructs a long-term, minimally restrictive diet excluding only proven triggers. This staged approach ensures both diagnostic clarity and nutritional adequacy, though it requires professional guidance for safe and effective implementation [27,28].

10.48047/jocaaa.2024.33.06.121

While the LFD reduces global IBS symptoms in many patients, it also has wider physiological implications. Restriction of FODMAPs alters fermentation patterns, decreasing colonic hydrogen and methane production, and can shift gut microbial composition. Additionally, reduced substrate load lessens osmotic diarrhea and distension, directly alleviating abdominal discomfort. Taken together, these mechanisms explain why the LFD has consistently outperformed traditional dietary advice in head-to-head clinical comparisons [29,30].

### C. Evidence on Efficacy of the Low FODMAP Diet in IBS

The clinical evidence supporting the LFD in IBS began with small open-label studies and rapidly progressed to randomized controlled trials (RCTs). These early trials consistently demonstrated significant improvements in global IBS symptoms, particularly abdominal pain, bloating, and stool consistency, compared with habitual or standard dietary advice. By consolidating diverse fermentable carbohydrates into one therapeutic framework, the LFD provided a reproducible strategy that could be tested across populations [31,32].

One of the landmark RCTs was conducted in Australia, where patients randomized to the LFD reported a substantial reduction in gastrointestinal symptom scores compared to controls. Subsequent multicenter studies confirmed that symptom relief occurred across all IBS subtypes, though patients with diarrhea-predominant IBS (IBS-D) appeared most responsive. Importantly, these improvements were evident within two to four weeks, supporting the short-term efficacy of the elimination phase [33,34].

Meta-analyses have further reinforced the effectiveness of the LFD. Pooled data indicate that 50–80% of IBS patients achieve clinically meaningful symptom relief, with the LFD consistently outperforming traditional dietary advice and, in some studies, gluten-free diets. Improvements are observed not only in abdominal pain and bloating but also in urgency, stool frequency, and overall quality of life. The consistency of these findings across diverse healthcare systems has led to widespread guideline endorsement [35–37].

Real-world evidence adds additional strength to the trial data. Observational studies and service evaluations demonstrate that the LFD is feasible in routine practice, with adherence rates ranging from 60–75% and sustained symptom relief for many patients. These findings are particularly important given concerns about whether the structured phases of the LFD could be realistically implemented outside research settings. Such data support the diet's scalability when delivered with adequate patient education and dietitian involvement [38,39].

Despite robust short-term efficacy, questions remain regarding long-term outcomes. Some patients relapse after reintroduction, while others struggle with adherence due to complexity or food costs. Furthermore, not all patients respond to the diet, underscoring the heterogeneity of IBS and the multifactorial nature of its pathophysiology. Current guidelines therefore position the LFD as a second-

10.48047/jocaaa.2024.33.06.121

line therapy, recommended after basic dietary and lifestyle advice have been attempted, with emphasis on individualized use rather than universal application [40,41].

### D. Impact of the Low FODMAP Diet on Symptom Subtypes of IBS

IBS is clinically categorized into subtypes based on predominant bowel habit: diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), mixed type (IBS-M), and unclassified. Symptom heterogeneity has long complicated dietary research, but studies consistently show that the LFD is effective across these subtypes, albeit with some variability in response patterns [42,43].

Among patients with IBS-D, the LFD demonstrates particularly strong efficacy. By reducing osmotic load and fermentation, the diet decreases stool frequency, urgency, and abdominal cramping. RCTs have confirmed that patients with IBS-D report greater improvements in stool consistency and urgency compared with IBS-C counterparts. These benefits likely reflect the direct reduction in colonic water content and luminal distension when FODMAP intake is restricted [44,45].

In IBS-C, results are more nuanced. While bloating and abdominal pain often improve, stool frequency and consistency may not change significantly. This suggests that while fermentation-related distension contributes to discomfort, constipation is more strongly driven by dysmotility than by dietary osmosis. For such patients, the LFD may best serve as a partial adjunct, focusing on reducing discomfort without necessarily normalizing bowel patterns. Additional interventions such as soluble fiber supplementation may be required in parallel [46,47].

For IBS-M and unclassified types, the LFD also yields benefit, primarily by reducing bloating, pain, and variable stooling patterns. These groups represent a substantial portion of real-world IBS populations, and clinical audits suggest that structured LFD implementation can provide meaningful relief even when symptom patterns fluctuate. However, predicting responders in these categories remains challenging, highlighting the need for biomarkers to better stratify patients [48,49].

Importantly, psychological comorbidities, such as anxiety and depression, frequently accompany all IBS subtypes and may influence diet responsiveness. While the LFD primarily targets gastrointestinal symptoms, secondary improvements in mood and quality of life are often reported, likely due to symptom relief rather than direct psychotropic effects. Recognizing these broader gains is critical in holistic IBS management, especially for patients whose daily function is heavily impaired by fluctuating bowel habits [50,51].

### E. Gut Microbiota and the Low FODMAP Diet

The gut microbiota is increasingly recognized as a central factor in IBS pathogenesis, influencing motility, visceral sensitivity, immune activity, and gut–brain signaling. FODMAPs serve as substrates for bacterial fermentation, and their restriction inevitably alters microbial ecology. Understanding these shifts is essential to evaluating both the benefits and potential drawbacks of the LFD [52,53].

10.48047/jocaaa.2024.33.06.121

Studies consistently show that the LFD reduces total colonic gas production, reflecting diminished fermentation activity. While this reduction underpins the clinical relief of bloating and pain, it also decreases the availability of fermentable substrates for beneficial microbes. Several trials have reported a decline in **Bifidobacteria abundance** after LFD initiation, raising concerns about long-term microbiome health. These changes, however, appear to be reversible once dietary diversity is reintroduced in the personalization phase [54,55].

Beyond compositional changes, the LFD modifies the metabolic output of the microbiome. Restricting fermentable carbohydrates lowers concentrations of short-chain fatty acids (SCFAs), particularly butyrate, which are important for colonocyte nutrition and epithelial barrier integrity. While reductions in SCFAs may contribute to symptom relief by dampening fermentation, they also highlight the need to balance symptom control with preservation of beneficial microbial functions [56,57].

Interindividual variability is a key feature of microbiome response to the LFD. Some patients exhibit marked microbial shifts, while others maintain relative stability, suggesting host genetics, baseline microbiota composition, and environmental exposures may influence outcomes. These findings raise the possibility of using microbiome signatures to predict dietary responders, though such approaches remain experimental at present [58,59].

Future research should focus on mitigating the potential negative effects of microbial depletion during the elimination phase. Strategies such as concurrent use of probiotics, selective prebiotics, or fiber fortification are being explored to preserve microbial diversity while retaining clinical benefits. Integrating microbiome monitoring into dietary trials will also be critical for understanding long-term implications of the LFD and guiding safer, more personalized approaches [60,61].

### F. Nutritional Adequacy and Risks of the Low FODMAP Diet

The LFD is inherently restrictive, and while effective in symptom control, it raises concerns about nutritional sufficiency, particularly if the elimination phase is prolonged. High-FODMAP foods often include fruits, vegetables, legumes, and dairy products, which are major contributors of fiber, calcium, and essential vitamins. Eliminating these groups without structured substitution can result in dietary imbalances that undermine long-term health [62,63].

Studies have reported that patients strictly adhering to the elimination phase of the LFD may consume reduced levels of calcium, magnesium, folate, vitamin C, and riboflavin. This is particularly concerning in populations already at risk for deficiencies, such as women of childbearing age or older adults. For example, dairy avoidance due to lactose restriction may lead to lower calcium intake unless low-FODMAP alternatives are introduced intentionally [64,65].

Fiber intake is another important consideration. While the LFD removes many fiber-rich foods such as wheat, beans, and certain fruits, it can also decrease prebiotic fiber that supports beneficial gut bacteria. This reduction may not only influence stool bulk and bowel regularity but also compromise

10.48047/jocaaa.2024.33.06.121

microbiome diversity and metabolic function. Therefore, clinicians often recommend retaining tolerated low-FODMAP fiber sources such as oats, chia seeds, and certain vegetables during the diet [66,67].

Nutritional risks are compounded by the practical complexity of the diet. Patients who self-manage without dietitian guidance may overly restrict, exclude entire food groups unnecessarily, or fail to reintroduce tolerated items, thereby extending the restrictive phase indefinitely. This pattern not only heightens the risk of deficiencies but can also lead to disordered eating tendencies, including food-related anxiety or avoidance behaviors [68,69].

To mitigate these risks, professional oversight is essential. Dietitians trained in LFD implementation can help patients navigate substitutions, identify culturally appropriate alternatives, and ensure dietary adequacy while still minimizing symptoms. Educational resources, food diaries, and mobile applications are increasingly used to support safe adherence. Ultimately, the goal is to use the LFD as a short-term diagnostic tool to identify triggers and then liberalize the diet during personalization, thereby minimizing long-term nutritional harm [70,71].

### G. Psychological and Quality of Life Outcomes

IBS is not only a gastrointestinal disorder but also a condition with significant psychological and quality-of-life (QoL) implications. Many patients report anxiety, depression, sleep disturbances, and reduced productivity, which in turn amplify symptom perception through the gut–brain axis. Because of this, any intervention that alleviates gastrointestinal symptoms has the potential to produce secondary mental health and QoL benefits [72,73].

Several studies have shown that the LFD leads to meaningful improvements in patient-reported QoL. Reductions in bloating, abdominal pain, and urgency correlate strongly with decreased social embarrassment and improved participation in daily activities. Patients frequently report greater confidence in eating outside the home and reduced healthcare visits for IBS-related symptoms, highlighting the broader functional impact of dietary therapy [74,75].

Psychological comorbidities also appear to improve with LFD adherence. Although the diet does not directly target mood disorders, alleviation of gastrointestinal symptoms reduces the chronic stress, anxiety, and anticipatory fear associated with unpredictable flares. In some studies, patients adhering to the LFD demonstrated significant decreases in standardized anxiety and depression scores, suggesting an indirect but clinically important psychological benefit [76,77].

However, not all findings are uniformly positive. Group-based education trials, for example, have demonstrated that while gastrointestinal symptoms improve, reductions in anxiety or depression may be less consistent. This variability underscores the importance of multimodal management, in which dietary therapy is complemented by psychological interventions such as cognitive behavioral therapy, gut-directed hypnotherapy, or mindfulness-based stress reduction [78,79].

10.48047/jocaaa.2024.33.06.121

Finally, it is worth acknowledging the potential for negative psychological consequences if the LFD is poorly implemented. Overly restrictive practices, lack of dietary diversity, or fear of symptom relapse upon reintroduction can foster food-related anxiety and social isolation. Clinicians must therefore balance symptom relief with a patient-centered approach that emphasizes flexibility, personalization, and reassurance that food diversity can be safely restored once triggers are identified [80,81].

### H. Role of the Family Physician in Low FODMAP Diet Implementation

Family physicians are often the first point of contact for patients with IBS, making their role pivotal in dietary management. They are responsible for confirming the diagnosis, excluding organic disease, and providing initial education about lifestyle measures and dietary triggers. By introducing the concept of the LFD early, family physicians can set realistic expectations and prepare patients for referral to dietitians when appropriate [82,83].

Primary care settings are also crucial for **patient triage**. Not every patient is a good candidate for the LFD; individuals with eating disorders, malnutrition risk, or food insecurity may fare poorly on a restrictive plan. Family physicians are well positioned to identify these red flags, ensuring that only motivated and suitable patients are referred for structured LFD counseling. This selective approach optimizes outcomes and prevents harm from inappropriate use [84,85].

Another critical responsibility of family physicians is **coordination of multidisciplinary care**. Effective LFD implementation often requires collaboration between gastroenterologists, dietitians, psychologists, and nursing staff. In this team, the family physician plays a central role in monitoring progress, reinforcing adherence, and managing comorbidities such as anxiety, depression, or sleep disturbance. Regular follow-up visits provide an opportunity to assess both gastrointestinal and psychosocial outcomes [86,87].

Family physicians can also mitigate the complexity of the diet by offering **practical tools and educational resources**. These include evidence-based dietary handouts, smartphone applications (such as those developed by Monash University), and structured food diaries. By providing clear and accessible resources, physicians help patients maintain confidence and reduce the risk of excessive restriction, which could otherwise lead to nutritional deficits [88,89].

Finally, the family physician's role extends to **long-term monitoring**. Once patients have completed the elimination and reintroduction phases under dietitian guidance, family physicians remain responsible for ensuring nutritional adequacy, monitoring psychosocial health, and adjusting management plans if symptoms recur. This ongoing support underscores the central importance of family medicine in delivering holistic, continuous, and patient-centered care for IBS [90,91].

### I. Conclusion

The low FODMAP diet has emerged as one of the most effective dietary strategies for managing irritable bowel syndrome. By targeting fermentable carbohydrates that drive luminal distension, gas

10.48047/jocaaa.2024.33.06.121

production, and symptom flares, the LFD offers a mechanistically sound and clinically validated approach. Evidence from randomized controlled trials, meta-analyses, and real-world practice consistently shows significant improvement in abdominal pain, bloating, urgency, and stool consistency for a majority of patients.

Despite its proven efficacy, the LFD is not without challenges. The restrictive nature of the elimination phase, the potential for nutritional inadequacy, and the risk of negative effects on the gut microbiota underscore the importance of structured, time-limited use under professional guidance. The staged process of restriction, reintroduction, and personalization is essential for ensuring that patients achieve long-term dietary diversity while still maintaining symptom control.

Equally important is the recognition that IBS is a biopsychosocial disorder. While dietary modification addresses one component of the pathophysiology, comprehensive care requires integrating psychological support, lifestyle modification, and pharmacologic options where appropriate. In this context, family physicians are uniquely positioned to coordinate care, provide education, and ensure ongoing monitoring.

Looking forward, advances in microbiome science, personalized nutrition, and digital health tools are likely to refine and individualize the LFD approach. Large-scale, long-term trials will be essential to strengthen the evidence base and define best practices for sustainable implementation. Ultimately, the goal is to deliver a patient-centered strategy that not only relieves symptoms but also enhances quality of life, empowers self-management, and supports holistic well-being.

## REFERENCES


1. Soncini M, Stasi C, Usai Satta P, Milazzo G, Bianco M, et al. IBS clinical management in Italy: The AIGO survey. *Dig Liver Dis*. 2019;51(6):782–9.
2. Chuy DS, Wi RS, Tadros M. Irritable bowel syndrome: Current landscape of diagnostic guidelines and therapeutic strategies. *Gastroenterol Insights*. 2024;15(3):786–809.
3. Xu C, Song Z, Hu JY, Li X, Wang Y. Global research trend and hotspot in the low FODMAP diet: A bibliometric analysis. *J Health Popul Nutr*. 2024;43:63.
4. Atzler J, Sahin A, Gallagher E, Zannini E, Arendt E. Characteristics and properties of fibers suitable for a low FODMAP diet – an overview. *Trends Food Sci Technol*. 2021;112:10–19.
5. Ahlawat GM, Singh PK. Methods of determining irritable bowel syndrome and efficiency of probiotics in treatment: A review. *Curr Ther Res Clin Exp*. 2023;99:100721.
6. Morariu I-D, Avasilcai L, Vieriu M, Lupu VV, Morariu B-A, et al. Effects of a Low-FODMAP Diet on Irritable Bowel Syndrome in Both Children and Adults—A Narrative Review. *Nutrients*. 2023;15(10):2295.
7. Zhang H, Su Q. Low-FODMAP diet for irritable bowel syndrome: Insights from microbiome. *Nutrients*. 2025;17(3):544.
8. Sarvepalli SS, Vemula SL, Aramadaka S, Mannam R, Sankara N, et al. Digesting the Impact of Diet on Irritable Bowel Syndrome (IBS): Exploring Solutions for Controlling IBS. *Cureus*. 2023;15(9):e45279.

10.48047/jocaaa.2024.33.06.121


9. Lomer MCE. The low FODMAP diet in clinical practice: where are we and what are the long-term considerations? *Proc Nutr Soc*. 2024;83(1):17–27.
10. Tang HY, Jiang AJ, Wang XY, Wang H, Guan YY, et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. *Ann Transl Med*. 2021;9(14):1187.
11. Camilleri M. Diagnosis and treatment of irritable bowel syndrome: A review. *JAMA*. 2021;325(8):865–77.
12. Black CJ, Ford AC. Global burden of irritable bowel syndrome: Trends, predictions and risk factors. *Nat Rev Gastroenterol Hepatol*. 2020;17:473–86.
13. Ionescu VA, Gheorghe G, Georgescu TF, Bacalbasa N, Gheorghe F, et al. The latest data concerning the etiology and pathogenesis of irritable bowel syndrome. *J Clin Med*. 2024;13(17):5124.
14. Farmer AD, Wood E, Ruffle JK. An approach to the care of patients with irritable bowel syndrome. *CMAJ*. 2020;192(11):E275–82.
15. Naseri M, Morshedi M, Sadeghi A, Sadeghi O. Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome. *BMC Gastroenterol*. 2021;21(1):1–12.
16. Staudacher HM, Rossi M, Kaminski T, Dimidi E, Ralph FSE, et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. *Neurogastroenterol Motil*. 2022;34(4):e14241.
17. Eijsbouts C, Zheng T, Kennedy NA, Bonfiglio F, Anderson CA, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. *Nat Genet*. 2021;53(11):1543–52.
18. O'Connor A, Gill S, Neary E, White S, Ford AC. Impact of HADS Anxiety and Depression Scores on the Efficacy of Dietary Interventions for Irritable Bowel Syndrome. *Aliment Pharmacol Ther*. 2024;59(4):461–72.
19. Suchak KK, Almario CV, Liran O, Chernoff R, Spiegel BR. The Role of Virtual Reality in the Management of Irritable Bowel Syndrome. *Curr Gastroenterol Rep*. 2024;26(11):294–303.
20. Sugaya N. Work-related problems and the psychosocial characteristics of individuals with irritable bowel syndrome: an updated literature review. *Biopsychosoc Med*. 2024;18(1):12.
21. Xu C, Song Z, Hu JY, Li X, Wang Y. Global research trend and hotspot in the low FODMAP diet: A bibliometric analysis. *J Health Popul Nutr*. 2024;43:63.
22. Bertin L, Zanconato M, Crepaldi M, Marasco G, Cremon C, et al. The role of the FODMAP diet in IBS. *Nutrients*. 2024;16(3):370.
23. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology*. 2014;146(1):67–75.e5.
24. Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. *Gastroenterology*. 2015;149(6):1399–407.e2.
25. Roest BR, Dobbs BA, Chapman B, Batman LA, O'Brien JA, et al. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. *Int J Clin Pract*. 2013;67(9):895–903.
26. Goyal O, Batta S, Nohria S, Kishore H, Goyal P, Sehgal R, et al. Low FODMAP diet in patients with diarrhoea-predominant irritable bowel syndrome: A prospective, randomised trial. *J Gastroenterol Hepatol*. 2021;36(8):2107–15.
27. Sultan N, Varney JE, Halmos EP, Biesiekierski JR, Yao CK, et al. How to implement the 3-phase FODMAP diet into gastroenterological practice. *J Neurogastroenterol Motil*. 2022;28(3):343–56.
28. Thomassen RA, Luque V, Assa A, Borrelli O, Broekaert I, et al. An ESPGHAN Position Paper on the Use of Low-FODMAP Diet in Pediatric Gastroenterology. *J Pediatr Gastroenterol Nutr*. 2022;75(3):356–68.
29. Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: Systematic review and network meta-analysis. *Gut*. 2022;71(6):1117–26.
30. Wang J, Yang P, Zhang L, Hou X. A low-FODMAP diet improves the global symptoms and bowel habits of adult IBS patients: A systematic review and meta-analysis. *Front Nutr*. 2021;8:683191.
31. Altobelli E, Del Negro V, Angeletti PM, Latella G. Low-FODMAP diet improves irritable bowel syndrome symptoms: A meta-analysis. *Nutrients*. 2017;9(9):940.
32. Orlando A, Tutino V, Baldassarre ME, Vitale A, Altomare DF, et al. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: A systematic review and meta-analysis. *Eur J Nutr*. 2020;59(8):389–408.
33. Algera JP, Demir D, Törnblom H, Nybacka S, Simrén M, et al. Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome, and clinical response could be predicted by symptom severity: A randomized crossover trial. *Clin Nutr*. 2022;41(12):2792–800.
34. Rej A, Shaw CC, Buckle RL, Trott N, Agrawal A, et al. The low FODMAP diet for IBS: A multicenter UK study assessing long-term follow-up. *Dig Liver Dis*. 2021;53(11):1404–11.
35. O'Keeffe M, Jansen C, Martin L, Williams M, Seamark L, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. *Neurogastroenterol Motil*. 2018;30:e13154.
36. De Palma G, Bercik P. Long-term personalized low FODMAP diet in IBS. *Neurogastroenterol Motil*. 2022;34(5):e14356.
37. Bardacke JA, Yarrow L, Rosenkranz SK. The long-term effects of a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet for irritable bowel syndrome management. *Curr Dev Nutr*. 2023;7(9):101997.
38. Weynants A, Goossens L, Genetello M, De Looze D, Van Winckel M. The long-term effect and adherence of a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet in patients with irritable bowel syndrome. *J Hum Nutr Diet*. 2020;33(2):159–69.
39. Gravina AG, Dallio M, Romeo M, Di Somma A, Cotticelli G, Loguercio C, et al. Adherence and effects derived from FODMAP diet on irritable bowel syndrome: A real-life evaluation of a large follow-up observation. *Nutrients*. 2020;12(4):928.
40. Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. *Am J Gastroenterol*. 2021;116(1):17–44.
41. Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. *Gut*. 2021;70(7):1214–40.
42. Dean G, Chey SW, Chey WD. The low FODMAP diet improves abdominal and overall symptoms in patients with all subtypes of irritable bowel syndrome: Real world evidence from a meal-delivery program. *Am J Gastroenterol*. 2022;117(10S):e37–8.
43. Krieger Grübel C, Hutter S, Hiestand M, Brenner I, Güsewell S, et al. Treatment efficacy of a low FODMAP diet compared to a low-lactose diet in IBS patients: A randomized, cross-over designed study. *Clin Nutr ESPEN*. 2020;40:83–9.

10.48047/jocaaa.2024.33.06.121


44. Nordin E, Landberg R, Hellström PM, Brunius C. Exploration of differential responses to FODMAPs and gluten in people with irritable bowel syndrome: A double-blind randomized cross-over challenge study. *Metabolomics*. 2024;20:21.
45. Kortlever TL, Ten Bokkel Huinink S, Offereins M, Hebblethwaite C, O'Brien L, et al. Low-FODMAP diet is associated with improved quality of life in IBS patients—a prospective observational study. *Nutr Clin Pract*. 2019;34(4):623–30.
46. Paduano D, Cingolani A, Tanda E, Usai P. Effect of three diets (low-FODMAP, gluten-free and balanced) on irritable bowel syndrome symptoms and health-related quality of life. *Nutrients*. 2019;11(7):1561.
47. Chan MMH, Zarate-Lopez N, Martin L. Group education on the low FODMAP diet improves gastrointestinal symptoms but neither anxiety nor depression in irritable bowel syndrome. *J Hum Nutr Diet*. 2022;35(3):425–34.
48. Chan M, Zarate-Lopez N, Martin L. Group education on the low FODMAP diet improves gastrointestinal symptoms but neither anxiety nor depression in irritable bowel syndrome. *J Hum Nutr Diet*. 2022;35(3):425–34.
49. Clevers E, Tran M, Van Oudenhove L, Störsrud S, Böhn L, Törnblom H, Simrén M. Adherence to diet low in fermentable carbohydrates and traditional diet for irritable bowel syndrome. *Nutrition*. 2020;73:110719.
50. Foulkes R, Shah P, Twomey A, Dami L, Jones D, et al. A service evaluation of FODMAP restriction, FODMAP reintroduction and long-term follow-up in the dietary management of irritable bowel syndrome. *J Hum Nutr Diet*. 2025;38(1):e13393.
51. Gravina AG, Dallio M, Romeo M, Di Somma A, Cotticelli G, Loguercio C, et al. Adherence and effects derived from FODMAP diet on irritable bowel syndrome: A real-life evaluation of a large follow-up observation. *Nutrients*. 2020;12(4):928.
52. Staudacher HM, Rossi M, Kaminski T, Dimidi E, Ralph FSE, et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. *Neurogastroenterol Motil*. 2022;34(4):e14241.
53. Hillestad EMR, Steinsvik EK, Teige ES, Rasmussen SH, Brønstad I, et al. Nutritional safety and status following a 12-week strict low FODMAP diet in patients with irritable bowel syndrome. *Neurogastroenterol Motil*. 2024;36(7):e14814.
54. Ustaoğlu T, Tek NA, Yıldırım AE. Evaluation of the effects of the FODMAP diet and probiotics on irritable bowel syndrome (IBS) symptoms, quality of life, and depression in women with IBS. *J Hum Nutr Diet*. 2024;37(1):5–17.
55. Black CJ, Ford AC. Best management of irritable bowel syndrome. *Frontline Gastroenterol*. 2020;12(4):303–15.
56. Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, et al. Italian guidelines for the management of irritable bowel syndrome. *Dig Liver Dis*. 2023;55(2):187–207.
57. Patel N, Shackelford KB. Irritable bowel syndrome. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2024.
58. Hemy AR, Zhu K, Moosavi S. Diagnosis and management of irritable bowel syndrome in the primary care setting. *BC Med J*. 2024;66(8):292–8.
59. Chaudhuri S. Irritable bowel syndrome: Expert guidance on diagnosis and management of challenging cases. *Int J Res Med Sci*. 2024;12:3989–96.
60. Tetali B, Suresh S. Management of irritable bowel syndrome: a narrative review. *Transl Gastroenterol Hepatol*. 2024;9:26.
61. Hung TH, Wang CY, Lee HF. Update in diagnosis and management of irritable bowel syndrome. *Tzu Chi Med J*. 2023;35(4):306–11.
62. Sultan N, Varney JE, Halmos EP, Biesiekierski JR, Yao CK, et al. How to implement the 3-phase FODMAP diet into gastroenterological practice. *J Neurogastroenterol Motil*. 2022;28(3):343–56.
63. Stalder E. The Effects of a Low FODMAP Diet on People with Irritable Bowel Syndrome: A Literature Review. The Eleanor Mann School of Nursing Undergraduate Honors Theses. 2022.
64. Slomski A. The low-FODMAP diet helps IBS symptoms, but questions remain. *JAMA*. 2020;323(11):1029–31.
65. Clevers E, Tran M, Van Oudenhove L, Störsrud S, Böhn L, Törnblom H, Simrén M. Adherence to diet low in fermentable carbohydrates and traditional diet for irritable bowel syndrome. *Nutrition*. 2020;73:110719.
66. Staudacher HM, Rossi M, Kaminski T, Dimidi E, Ralph FSE, et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. *Neurogastroenterol Motil*. 2022;34(4):e14241.
67. Sultan N, Varney JE, Halmos EP, Biesiekierski JR, Yao CK, et al. How to implement the 3-phase FODMAP diet into gastroenterological practice. *J Neurogastroenterol Motil*. 2022;28(3):343–56.
68. Tuck CJ, Reed DE, Muir JG, Vanner SJ. Implementation of the low FODMAP diet in functional gastrointestinal symptoms: a real-world experience. *Neurogastroenterol Motil*. 2020;32(1):e13730.
69. Clevers E, Tran M, Van Oudenhove L, Störsrud S, Böhn L, Törnblom H, Simrén M. Adherence to diet low in fermentable carbohydrates and traditional diet for irritable bowel syndrome. *Nutrition*. 2020;73:110719.
70. Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, et al. Italian guidelines for the management of irritable bowel syndrome. *Dig Liver Dis*. 2023;55(2):187–207.
71. Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. *Gut*. 2021;70(7):1214–40.
72. Andrae DA, Patrick DL, Drossman DA, Covington PS. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal predominant irritable bowel syndrome patients. *Health Qual Life Outcomes*. 2013;11:208.
73. Costa L, Islam S, Anowar N, Latif A. Quality of Life of Chronic Heart Failure Patients. *Open J Nurs*. 2020;10(9):831–57.
74. Kortlever TL, Ten Bokkel Huinink S, Offereins M, Hebblethwaite C, O'Brien L, et al. Low-FODMAP diet is associated with improved quality of life in IBS patients—a prospective observational study. *Nutr Clin Pract*. 2019;34(4):623–30.
75. Chan MMH, Zarate-Lopez N, Martin L. Group education on the low FODMAP diet improves gastrointestinal symptoms but neither anxiety nor depression in irritable bowel syndrome. *J Hum Nutr Diet*. 2022;35(3):425–34.
76. O'Connor A, Gill S, Neary E, White S, Ford AC. Impact of HADS Anxiety and Depression Scores on the Efficacy of Dietary Interventions for Irritable Bowel Syndrome. *Aliment Pharmacol Ther*. 2024;59(4):461–72.
77. Eijsbouts C, Zheng T, Kennedy NA, Bonfiglio F, Anderson CA, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. *Nat Genet*. 2021;53(11):1543–52.
78. Suchak KK, Almario CV, Liran O, Chernoff R, Spiegel BR. The Role of Virtual Reality in the Management of Irritable Bowel Syndrome. *Curr Gastroenterol Rep*. 2024;26(11):294–303.
79. Sugaya N. Work-related problems and the psychosocial characteristics of individuals with irritable bowel syndrome: an updated literature review. *Biopsychosoc Med*. 2024;18(1):12.
80. Stalder E. The Effects of a Low FODMAP Diet on People with Irritable Bowel Syndrome: A Literature Review. The Eleanor Mann School of Nursing Undergraduate Honors Theses. 2022.

10.48047/jocaaa.2024.33.06.121


81. Gravina AG, Dallio M, Romeo M, Di Somma A, Cotticelli G, Loguercio C, et al. Adherence and effects derived from FODMAP diet on irritable bowel syndrome: A real-life evaluation of a large follow-up observation. *Nutrients*. 2020;12(4):928.
82. Hemy AR, Zhu K, Moosavi S. Diagnosis and management of irritable bowel syndrome in the primary care setting. *BC Med J*. 2024;66(8):292–8.
83. Chaudhuri S. Irritable bowel syndrome: Expert guidance on diagnosis and management of challenging cases. *Int J Res Med Sci*. 2024;12:3989–96.
84. Patel N, Shackelford KB. Irritable bowel syndrome. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2024.
85. Tetali B, Suresh S. Management of irritable bowel syndrome: a narrative review. *Transl Gastroenterol Hepatol*. 2024;9:26.
86. Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, et al. Italian guidelines for the management of irritable bowel syndrome. *Dig Liver Dis*. 2023;55(2):187–207.
87. Black CJ, Ford AC. Best management of irritable bowel syndrome. Frontline Gastroenterol. 2020;12(4):303–15.
88. Monash University. What is the purpose of a FODMAP diet? Monash FODMAP. 2025. Available at: https://www.monashfodmap.com/about-fodmap-and-ibs/what-is-the-fodmap-diet/
89. Foulkes R, Shah P, Twomey A, Dami L, Jones D, et al. A service evaluation of FODMAP restriction, FODMAP reintroduction and long-term follow-up in the dietary management of irritable bowel syndrome. *J Hum Nutr Diet*. 2025;38(1):e13393.
90. Hung TH, Wang CY, Lee HF. Update in diagnosis and management of irritable bowel syndrome. *Tzu Chi Med J*. 2023;35(4):306–11.
91. Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. *Gut*. 2021;70(7):1214–40.